USA flag logo/image

An Official Website of the United States Government

Novel Therapeutic Strategy for Gliomas

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75509
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
CA103571
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ONCONOVA THERAPEUTICS, INC.
375 PHEASANT RUN NEWTOWN, PA 18940-3423
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Novel Therapeutic Strategy for Gliomas
Agency: HHS
Contract: 1R43CA103571-01A1
Award Amount: $135,546.00
 

Abstract:

DESCRIPTION (PROVIDED BY APPLICANT): Malignant gliomas are characterized by their ability to swiftly and diffusely invade from their primary foci into the surrounding normal brain parenchyma, making them surgically incurable. The failure to control invasive subpopulations of cells may be the key cause of local glioma recurrence after radical tumor resection. Currently available therapeutic strategies have poor outcome and an effective solution may require attack on multiple aberrant mechanisms in these malignant cells. Onconova is developing novel, mechanism based, therapeutic agents that have differential effects on normal and cancer cells. The effect on cancer cells is pleiotropic and involves inhibition of cell growth as well as activation of apoptosis. Normal cells, such as endothelial cells involved in angiogenesis, are growth inhibited without induction of apoptosis. Our hypothesis is to screen this series of compounds that exhibit a broad range of effects on various genes that are involved in cell growth, invasion and angiogenesis. Preliminary data suggests that this strategy of impacting dual growth/death mechanisms with a small molecule drug is promising. The specific aims are 1) to expand the chemical structure and activity relationship of the drug and 2) to study the effect of Onconova Series compounds ON 01060, ON 01330, ON 01370, ON 01500, ON 01590 and ON 01910 on glioma growth, adhesion, migration and angiogenesis in in vitro models. The studies may provide valuable information about the role of these compounds in tumor cell adhesion, invasion and angiogenesis.

Principal Investigator:

Stanley C. Bell
6098447735
SCBELL@ONCONOVA.US

Business Contact:

Ramesh Kumar
6098447735
KUMAR@ONCONOVA.COM
Small Business Information at Submission:

Onconova Therapeutics, Inc.
993 Lenox Drive Suite 200 Lawrenceville, NJ 08648

EIN/Tax ID: 223627252
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No